COVID-19 Archive｜株式会社Smart119｜新型コロナウィルス感染症関連論文アーカイブ

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

2021.04.12

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

2021.04.12

Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract (Nature 2021.4.6)

2021.04.06

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 (Nature 2021.3.15)

2021.04.06

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

2021.03.16

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

2021.03.16

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

2021.03.15

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study (BMJ 2021.3.10)

2021.03.11

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study (Epub 2020.10.29)

2021.03.07

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial (JAMA 2021.3.4)

2021.03.05

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

2021.03.03

ROGUE ANTIBODIES COULD BE DRIVING SEVERE COVID-19 (Nature 2021.1.19)

2021.03.02

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

2021.03.02

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

2021.03.02

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 (NEJM 2021.2.25)

2021.03.01

Autoantibodies against type I IFNs in patients with life-threatening COVID-19 (Science 2020.10.23)

2021.02.25

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial (Lancet 2020.11.12)

2021.02.24

How soon will COVID-19 vaccines return life to normal? (Science 2021.2.16)

2021.02.15

COVID-19 Archive

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract (Nature 2021.4.6)

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 (Nature 2021.3.15)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study (BMJ 2021.3.10)

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study (Epub 2020.10.29)

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial (JAMA 2021.3.4)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

ROGUE ANTIBODIES COULD BE DRIVING SEVERE COVID-19 (Nature 2021.1.19)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 (NEJM 2021.2.25)

Autoantibodies against type I IFNs in patients with life-threatening COVID-19 (Science 2020.10.23)

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial (Lancet 2020.11.12)

How soon will COVID-19 vaccines return life to normal? (Science 2021.2.16)

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US--December 14, 2020-January 18, 2021(JAMA 2021.2.12)